---
title: "SSY Group Wins Chinese Approvals for Two Cardiovascular Injectables"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284150992.md"
description: "SSY Group Limited has received Chinese production and registration approval for two cardiovascular injectables: Diltiazem Hydrochloride for Injection and Propranolol Hydrochloride Injection. These approvals enhance the company's portfolio in acute cardiovascular care and strengthen its position in China's hospital drug market. The latest analyst rating for SSY Group (HK:2005) is a Buy with a price target of HK$5.00. The company focuses on developing high-quality injectable drugs for critical care in China."
datetime: "2026-04-27T04:07:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284150992.md)
  - [en](https://longbridge.com/en/news/284150992.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284150992.md)
---

# SSY Group Wins Chinese Approvals for Two Cardiovascular Injectables

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

SSY Group ( (HK:2005) ) has shared an announcement.

SSY Group Limited has secured production and registration approval in China for its Diltiazem Hydrochloride for Injection (10mg), classified as a type 4 chemical drug and deemed to have passed consistency evaluation. The product targets supraventricular tachycardia, perioperative hypertensive crises, hypertensive emergencies and unstable angina, reinforcing the group’s presence in acute cardiovascular care.

The company has also received approval for Propranolol Hydrochloride Injection in two dosage formats, recognized as a type 3 drug with passed consistency evaluation, following earlier registration approval for its bulk drug. These new approvals broaden SSY Group’s cardiovascular injectable portfolio, enhancing its competitive position in China’s hospital drug market and signaling continued progress in product development that may support future revenue growth.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

**More about SSY Group**

SSY Group Limited is a pharmaceutical company based in Hong Kong that develops and manufactures injectable drugs for the hospital and clinical markets. The group focuses on regulated prescription medicines in China, targeting cardiovascular and other critical care indications where high-quality, NMPA-approved injectable formulations are in demand.

**YTD Price Performance:** -14.13%

**Average Trading Volume:** 9,304,684

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$7.17B

See more data about 2005 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02005.HK](https://longbridge.com/en/quote/02005.HK.md)

## Related News & Research

- [SSY Group Wins Trio of NMPA Approvals, Expanding China Drug Portfolio](https://longbridge.com/en/news/285859735.md)
- [SSY Group Wins Key China Drug Approvals, Expands Chronic and Pediatric Portfolio](https://longbridge.com/en/news/285308388.md)
- [Avalere Health launches ‘Within Reach’, a new oncology anthology about what it really means to navigate cancer access, treatment, and care](https://longbridge.com/en/news/287075968.md)
- [SSY Group Profit Halves as Revenue and Margins Slide in Challenging 2025](https://longbridge.com/en/news/280725971.md)
- [Dr Reddy's Laboratories launches generic Semaglutide injection in Canada](https://longbridge.com/en/news/286635919.md)